Placebo, nocebo, and neuropathic pain

Pain

Volumn 157, Issue , 2016, Pages S98-S105

  Vase, Lene ^a,b   Skyt, Ina ^a,b   Hall, Kathryn T ^c,d  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Neuropathic pain; Nocebo hyperalgesia; Placebo analgesia; Randomized controlled trial

Indexed keywords

ANALGESIA; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DISEASE COURSE; GENOTYPE; HEREDITY; HUMAN; HYPERALGESIA; IDIOPATHIC PAIN; NEUROBIOLOGY; NEUROPATHIC PAIN; NOCEBO EFFECT; NOCICEPTION; NOCICEPTIVE PAIN; PAIN; PLACEBO EFFECT; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; NEURALGIA; PAIN MEASUREMENT; PSYCHOLOGY;

HUMANS; NEURALGIA; PAIN MEASUREMENT; PLACEBO EFFECT;

EID: 84961310967     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1097/j.pain.0000000000000445     Document Type: Conference Paper

References (91)

1. Benedetti F. Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu Rev Pharmacol Toxicol 2008;48:33-60.
2. Benedetti F, Amanzio M, Vighetti S, Asteggiano G. The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J Neurosci 2006;26:12014-22.
3. Kong J, Gollub RL, Polich G, Kirsch I, Laviolette P, Vangel M, Rosen B, Kaptchuk TJ. A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect. J Neurosci 2008;28: 13354-62.
4. Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol 2008;59:565-90.
5. Amanzio M, Pollo A, Maggi G, Benedetti F. Response variability to analgesics: a role for non-specific activation of endogenous opioids. PAIN 2001;90:205-15.
6. Benedetti F, Pollo A, Lopiano L, Lanotte M, Vighetti S, Rainero I. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci 2003;23: 4315-23.
7. Levine JD, Gordon NC. Influence of the method of drug administration on analgesic response. Nature 1984;312:755-6.
8. Levine JD, Gordon NC, Fields HL. The mechanism of placebo analgesia. Lancet 1978;2:654-7.
9. Loeser JD, Treede RD. The Kyoto protocol of IASP Basic Pain Terminology. PAIN 2008;137:473-7.
10. Craggs JG, Price DD, Verne GN, Perlstein WM, Robinson MM. Functional brain interactions that serve cognitive-affective processing during pain and placebo analgesia. Neuroimage 2007;38:720-9.
11. Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, Kowalczykowski M, Miller FG, Kirsch I, Lembo AJ. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One 2010;5:e15591.
12. Price DD, Craggs J, Verne GN, Perlstein WM, Robinson ME. Placebo analgesia is accompanied by large reductions in pain-related brain activity in irritable bowel syndrome patients. PAIN 2007;127:63-72.
13. Vase L, Robinson ME, Verne GN, Price DD. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation. PAIN 2003;105:17-25.
14. Vase L, Robinson ME, Verne GN, Price DD. Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms. PAIN 2005;115:338-47.
15. Verne GN, Robinson ME, Vase L, Price DD. Reversal of visceral and cutaneous hyperalgesia by local rectal anesthesia in irritable bowel syndrome (IBS) patients. PAIN 2003;105:223-30.
16. Kupers R, Maeyaert J, Boly M, Faymonville ME, Laureys S. Naloxoneinsensitive epidural placebo analgesia in a chronic pain patient. Anesthesiology 2007;106:1239-42.
17. Piche M, Bouin M, Arsenault M, Poitras P, Rainville P. Decreased pain inhibition in irritable bowel syndrome depends on altered descenDing modulation and higher-order brain processes. Neuroscience 2011;195: 166-75.
18. Tirlapur SA, Priest L, Daniels JP, Khan KS. How do we define the term idiopathic? Curr Opin Obstet Gynecol 2013;25:468-73.
19. Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, Cohen M, Evers S, Finnerup NB, First MB, Giamberardino MA, Kaasa S, Kosek E, Lavand'homme P, Nicholas M, Perrot S, Scholz J, Schug S, Smith BH, Svensson P, Vlaeyen JW, Wang SJ. A classification of chronic pain for ICD-11. PAIN 2015;156:1003-7.
20. Jensen TS, Baron R, Haanpaa M, Kalso E, Loeser JD, Rice AS, Treede RD. A new definition of neuropathic pain. PAIN 2011;152:2204-5.
21. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpaa M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162-73.
22. HäuserW, Bartram-Wunn E, Bartram C, Reinecke H, Tolle T. Systematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related predictors. PAIN 2011;152:1709-17.
23. Dworkin RH, Turk DC, Peirce-Sandner S, Burke LB, Farrar JT, Gilron I, Jensen MP, Katz NP, Raja SN, Rappaport BA, Rowbotham MC, Backonja MM, Baron R, Bellamy N, Bhagwagar Z, Costello A, Cowan P, Fang WC, Hertz S, Jay GW, Junor R, Kerns RD, Kerwin R, Kopecky EA, Lissin D, Malamut R, Markman JD, McDermott MP, Munera C, Porter L, Rauschkolb C, Rice AS, Sampaio C, Skljarevski V, Sommerville K, Stacey BR, Steigerwald I, Tobias J, Trentacosti AM, Wasan AD, Wells GA, Williams J, Witter J, Ziegler D. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. PAIN 2012;153:1148-58.
24. Enck P, Bingel U, Schedlowski M, Rief W. The placebo response in medicine:minimize, maximize or personalize? Nat Rev Drug Discov 2013; 12:191-204.
25. Rief W, Bingel U, Schedlowski M, Enck P. Mechanisms involved in placebo and nocebo responses and implications for drug trials. Clin Pharmacol Ther 2011;90:722-6.
26. Vase L, Amanzio M, Price DD. Nocebo vs. placebo: the challenges of trial design in analgesia research. Clin Pharmacol Ther 2015;97:143-50.
27. Kirsch I. The placebo effect revisited: lessons learned to date. Complement Ther Med 2013;21:102-4.
28. Benedetti F. Placebo effects: understanDing the mechanisms in health and disease. Second edition, Oxford University Press, Oxford, United Kingdom. 2014.
29. Vase L, Riley JL III, Price DD. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. PAIN 2002;99: 443-52.
30. Moerman DE, Jonas WB. Deconstructing the placebo effect and finDing the meaning response. Ann Intern Med 2002;136:471-6.
31. Amanzio M, Corazzini LL, Vase L, Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. PAIN 2009;146:261-9.
32. Mitsikostas DD, Mantonakis LI, Chalarakis NG. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia 2011;31:550-61.
33. Papadopoulos D, Mitsikostas DD. A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. J Neurol 2012;259: 436-47.
34. Petersen GL, Finnerup NB, Colloca L, Amanzio M, Price DD, Jensen TS, Vase L. The magnitude of nocebo effects in pain: a meta-analysis. PAIN 2014;155:1426-34.
35. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344:1594-602.
36. Vase L, Petersen GL, Riley JL III, Price DD. Factors contributing to large analgesic effects in placebo mechanism studies conducted between 2002 and 2007. PAIN 2009;145:36-44.
37. Petersen GL, Finnerup NB, Grosen K, Pilegaard HK, Tracey I, Benedetti F, Price DD, Jensen TS, Vase L. Expectations and positive emotional feelings accompany reductions in ongoing and evoked neuropathic pain following placebo interventions. PAIN 2014;155:2687-98.
38. Petersen GL, Finnerup NB, Norskov KN, Grosen K, Pilegaard HK, Benedetti F, Price DD, Jensen TS, Vase L. Placebo manipulations reduce hyperalgesia in neuropathic pain. PAIN 2012;153:1292-300.
39. Baron R, Hans G, Dickenson AH. Peripheral input and its importance for central sensitization. Ann Neurol 2013;74:630-6.
40. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 2009;10:895-926.
41. Li J, Simone DA, Larson AA. Windup leads to characteristics of central sensitization. PAIN 1999;79:75-82.
42. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. PAIN 2001;91:165-75.
43. Staud R, Weyl EE, Riley JL III, Fillingim RB. Slow temporal summation of pain for assessment of central pain sensitivity and clinical pain of fibromyalgia patients. PLoS One 2014;9:e89086.
44. Klinger R, Schmitz J, Benson S, Elsenbruch S, Kamping S, Flor H. Schmerzreduktion durch Variation von Kontextreizen: möglichkeiten zur Selbstwirksamkeit in der Schmerztherapie? Der Schmerz 2013;27: 47-9.
45. De Pascalis V, Chiaradia C, Carotenuto E. The contribution of suggestibility and expectation to placebo analgesia phenomenon in an experimental setting. PAIN 2002;96:393-402.
46. Montgomery GH, Kirsch I. Classical conditioning and the placebo effect. PAIN 1997;72:107-13.
47. Price DD, Milling LS, Kirsch I, Duff A, Montgomery GH, Nicholls SS. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. PAIN 1999;83:147-56.
48. Zubieta JK, Bueller JA, Jackson LR, Scott DJ, Xu Y, Koeppe RA, Nichols TE, Stohler CS. Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci 2005;25:7754-62.
49. Zubieta JK, Yau WY, Scott DJ, Stohler CS. Belief or need? Accounting for individual variations in the neurochemistry of the placebo effect. Brain Behav Immun 2006;20:15-26.
50. Price DD, Barrell JJ. Inner experience and neuroscience: merging both perspectives. Cambridge: MIT Press, 2012.
51. Colloca L, Miller FG. The nocebo effect and its relevance for clinical practice. Psychosom Med 2011;73:598-603.
52. Schmid J, Theysohn N, Gass F, Benson S, Gramsch C, Forsting M, Gizewski ER, Elsenbruch S. Neural mechanisms mediating positive and negative treatment expectations in visceral pain: a functional magnetic resonance imaging study on placebo and nocebo effects in healthy volunteers. PAIN 2013;154:2372-80.
53. AmanzioM,Benedetti F, PorroCA, Palermo S,Cauda F. Activation likelihood estimation meta-analysis of brain correlates of placebo analgesia in human experimental pain. Hum Brain Mapp 2013;34:738-52.
54. Büchel C, Geuter S, Sprenger C, Eippert F. Placebo analgesia: a predictive coDing perspective. Neuron 2014;81:1223-39.
55. Craggs JG, Price DD, Perlstein WM, Verne GN, Robinson ME. The dynamic mechanisms of placebo induced analgesia: evidence of sustained and transient regional involvement. PAIN 2008;139:660-9.
56. Craggs JG, Price DD, Robinson ME. Enhancing the placebo response: functional magnetic resonance imaging evidence of memory and semantic processing in placebo analgesia. J Pain 2014;15:435-46.
57. Eippert F, Finsterbusch J, Bingel U, Buchel C. Direct evidence for spinal cord involvement in placebo analgesia. Science 2009;326:404.
58. Dib-Hajj SD, Waxman SG. Translational pain research: lessons from genetics and genomics. Sci Transl Med 2014;6:249sr244.
59. de la Fuente-Fernandez R, Lidstone S, Stoessl AJ. Placebo effect and dopamine release. J Neural Transm Suppl 2006:415-18.
60. Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, Ruth TJ, de la Fuente-Fernandez R, Phillips AG, Stoessl AJ. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry 2010;67:857-65.
61. Zubieta JK, Stohler CS. Neurobiological mechanisms of placebo responses. Ann N Y Acad Sci 2009;1156:198-210.
62. Hall KT, Loscalzo J, Kaptchuk TJ. Genetics and the placebo effect: the placebome. Trends Mol Med 2015;21:285-94.
63. Diatchenko L, Nackley AG, Tchivileva IE, Shabalina SA, MaixnerW. Genetic architecture of human pain perception. Trends Genet 2007;23:605-13.
64. Kambur O, Mannisto PT. Catechol-O-methyltransferase and pain. Int Rev Neurobiol 2010;95:227-79.
65. Martinez-Jauand M, Sitges C, Rodriguez V, Picornell A, Ramon M, Buskila D, Montoya P. Pain sensitivity in fibromyalgia is associated with catechol-O-methyltransferase (COMT) gene. Eur J Pain 2013;17:16-27.
66. Chen Q, He G, Qin W, Chen QY, Zhao XZ, Duan SW, Liu XM, Feng GY, Xu YF, St Clair D, Li M, Wang JH, Xing YL, Shi JG, He L. Family-based association study of synapsin II and schizophrenia. Am J Hum Genet 2004;75:873-7.
67. Hall KT, Lembo AJ, Kirsch I, Ziogas DC, Douaiher J, Jensen KB, Conboy LA, Kelley JM, Kokkotou E, Kaptchuk TJ. Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One 2012;7:e48135.
68. Yu R, Gollub RL, Vangel M, Kaptchuk T, Smoller JW, Kong J. Placebo analgesia and reward processing: integrating genetics, personality, and intrinsic brain activity. Hum Brain Mapp 2014;35:4583-93.
69. Pecina M, Love T, Stohler CS, Goldman D, Zubieta JK. Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures. Neuropsychopharmacology 2015;40:957-65.
70. Peciña M, Martinez-Jauand M, Hodgkinson C, Stohler CS, Goldman D, Zubieta JK. FAAH selectively influences placebo effects. Mol Psychiatry 2014;19:385-91.
71. Wrobel N, Wiech K, Forkmann K, Ritter C, Bingel U. Haloperidol blocks dorsal striatum activity but not analgesia in a placebo paradigm. Cortex 2014;57:60-73.
72. Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioningactivated specific subsystems. J Neurosci 1999;19:484-94.
73. Benedetti F, Amanzio M, Rosato R, Blanchard C. Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nat Med 2011;17: 1228-30.
74. Benedetti F, Thoen W, Blanchard C, Vighetti S, Arduino C. Pain as a reward: changing the meaning of pain from negative to positive coactivates opioid and cannabinoid systems. PAIN 2013;154:361-7.
75. Kessner S, Sprenger C, Wrobel N, Wiech K, Bingel U. Effect of oxytocin on placebo analgesia: a randomized study. JAMA 2013;310:1733-5.
76. Medoff ZM, Colloca L. Placebo analgesia: understanDing the mechanisms. PAIN Manag 2015;5:89-96.
77. Colloca L, Pine DS, Ernst M, Miller FG, Grillon C. Vasopressin boosts placebo analgesic effects in women: a randomized trial. Biol Psychiatry 2015. 10. 1016/j. biopsych. 2015. 07. 019. [Epub ahead of print].
78. Bingel U, Wanigasekera V, Wiech K, Ni Mhuircheartaigh R, Lee MC, Ploner M, Tracey I. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med 2011;3:70ra14.
79. Benedetti F, Amanzio M, Casadio C, Oliaro A, Maggi G. Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. PAIN 1997;71:135-40.
80. Wendt L, Albring A, Benson S, Engler H, Engler A, Hinney A, Rief W, Witzke O, Schedlowski M. Catechol-O-methyltransferase Val158Met polymorphism is associated with somatosensory amplification and nocebo responses. PLoS One 2014;9:e107665.
81. Hall KT, Tolkin BR, Chinn GM, Kirsch I, Kelley JM, Lembo AJ, Kaptchuk TJ, Kokkotou E, Davis RB, Conboy LA. Conscientiousness is modified by genetic variation in catechol-O-methyltransferase to reduce symptom complaints in IBS patients. Brain Behav 2015;5:39-44.
82. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. PAIN 2010;150:573-81.
83. Katz J, FinnerupNB,DworkinRH. Clinical trial outcome in neuropathic pain: relationship to study characteristics. Neurology 2008;70:263-72.
84. Simpson DM, Rice AS, Emir B, Landen J, Semel D, Chew ML, Sporn J. A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy. PAIN 2014;155:1943-54.
85. Lund K, Vase L, Petersen GL, Jensen TS, Finnerup NB. Randomised controlled trials may underestimate drug effects: balanced placebo trial design. PLoS One 2014;9:e84104.
86. Diener HC, Dowson AJ, Ferrari M, Nappi G, Tfelt-Hansen P. Unbalanced randomization influences placebo response: scientific versus ethical issues around the use of placebo in migraine trials. Cephalalgia 1999;19: 699-700.
87. Fields HL, Price DD. Toward a neurobiology of placebo analgesia. In: Harrington A, editor. The placebo effect. Boston: Harvard University Press, 1997. p. 93-116.
88. Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, Jacobson EE, Kirsch I, Schyner RN, NamBH, Nguyen LT, Park M, Rivers AL, McManus C, Kokkotou E, Drossman DA, Goldman P, Lembo AJ. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008;336:999-1003.
89. Katz N. Methodological issues in clinical trials of opioids for chronic pain. Neurology 2005;65(suppl 4):S32-49.
90. Price DD, Vase L. The contributions of desire, expectation and reduced negative emotions to placebo anti-hyperalgesia in irritable bowel syndrome. In: Colloca L, Flaten M, Meissner K, editors. Placebo and pain from bench to bedside. Amsterdam: Academic Press Inc, 2013. p. 215-16.
91. Vase L, Vollert J, Finnerup NB, Miao X, Atkinson G, Marshall S, Nemeth R, Lange B, Liss C, Price DD, Maier C, Jensen TS, Segerdahl M. Predictors of the placebo analgesia response in randomized controlled trials of chronic pain: a meta-analysis of the individual data from nine industrially sponsored trials. PAIN 2015;156:1795-802.